Metabolic Risk Following Gestational Diabetes Mellitus
- Conditions
- Gestational Diabetes
- Interventions
- Other: Blood sampling and OGTT
- Registration Number
- NCT02133729
- Lead Sponsor
- Hospices Civils de Lyon
- Brief Summary
Gestational diabetes (GDM) is defined by abnormal glucose tolerance during gestation. This complication occurs in 4-10% and is associated with fetal complications and macrosomia. In addition, women with GDM have an increased risk to develop type 2 diabetes after delivery. Despite recommendations, it is difficult to follow-up all women with GDM during the postpartum period due to high numbers of subjects that exceed usual healthcare resources. It is therefore necessary to focus clinical attention toward women at high risk of type 2 diabetes in order to set adequate preventive strategies.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- Female
- Target Recruitment
- 255
-
Women aged over 18years old
-
Women with the criteria of GDM during pregnancy at 21-35 weeks of gestation (one situation):
- After a 75g Oral Glucose Tolerance Test (OGTT - WHO criteria) with blood glucose (BG) values at T60≥180mg/dl and/or T120≥153mg/dl
- An O. Sullivan test following a 100g oral glucose load with at least two pathological values (T60 ≥ 180mg/dl and/or T120 ≥ 155mg/dl and/or T180 ≥ 140mg/dl)
- With a fasting BG value ≥92mg/dl
-
Women with signed informed consent
- Women aged less than 18years old
- Women with pregestational type 2 diabetes
- Women without signed informed consent
- Women who does not read and/or understand french language
- Women not affiliated to the health care system
- Women with recent infection (<1month) and/or on steroids or anti-inflammatory drugs.
- Women with chronic diseases
- Women with a disable state
- Women with normal glucose tolerance
- Women already incorporated in another clinical study that could interfere with the present study
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- SINGLE_GROUP
- Arm && Interventions
Group Intervention Description Gestational diabete Blood sampling and OGTT -
- Primary Outcome Measures
Name Time Method Metabolic index value 3 months after delivery (+/- 15 days) The primary objective relies on Receiver Operating Characteristic (ROC) curves of metabolic index values using peripheral markers during gestation : C-Reactive Protein ultrasensitive (CRPus), malonaldehyde (MDA) and adiponectin (index = (CRP + MDA)/adiponectin) to detect an abnormal glucose tolerance at 3 months (+/- 15 days) after delivery (M3) during a 75g oral glucose tolerance test (T0\>110mg/dl and/or T120 \>145mg/dl). The rationale for the index relies on lower adiponectin values high CRPus levels and MDA values during insulin resistance chronic inflammatory status and oxidative stress.
- Secondary Outcome Measures
Name Time Method Prevalence of abnormal glucose tolerance in women with GDM 3 months (+/- 15 days) following delivery
Trial Locations
- Locations (7)
Groupement Hospitalier des Portes du Sud - Service d'Endocrinologie Diabétologie Nutrition
🇫🇷Venissieux, France
CHU Grenoble - Clinique d'Endocrinologie Diabétologie Nutrition
🇫🇷Grenoble, France
CHU Saint Etienne - Hôpital Nord - Service d'endocrinologie, diabètes, nutrition
🇫🇷Saint Etienne, France
Hospices Civils de Lyon - Groupement Hospitalier Sud - Service d'Endocrinologie, Diabète, Nutrition
🇫🇷Pierre Benite, France
Centre Hospitalier de Givors - Hôpital de Montgelas - Service de médicine 8
🇫🇷Givors, France
Hospices Civils de Lyon - Hôpital Femme-Mère-Enfant - Service de gynécologie obstétrique
🇫🇷Bron, France
CHU Clermont-Ferrand - Hôpital Gabriel Montpied - Service d'endocrinologie
🇫🇷Clermont-ferrand, France